Chief Scientific Officer
Becky Schweighardt is an innovative drug developer with broad development experience across multiple global drug approvals in rare disease. Dr. Schweighardt is a trained immunologist and virologist who specializes in disease pathology. Her drug development experience reaches across all stages of development from discovery to post-marketing and across multiple drug modalities, including protein therapeutics, gene therapies, oligo nucleotides, and small molecules. She has 20+ years of academic and industry experience and spent the last 10 years developing therapeutics for rare disease at BioMarin Pharmaceutical. Dr. Schweighardt is proficient at building and leading high-performing drug development teams and guides with an inspirational leadership style focused on aspirational vision and shared purpose.